Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
ADC Therapeutics SA (ADCT) had Consolidated Net Income/Loss of $-32.97M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$20.85M |
|
$-32.97M |
|
$3.62M |
|
$17.24M |
|
$46.10M |
|
$-25.25M |
|
$-7.72M |
|
$-32.97M |
|
$-32.97M |
|
$-32.97M |
|
$-32.97M |
|
|
Consolidated Net Income/Loss |
$-32.97M |
$-32.97M |
|
$-25.25M |
|
$-25.13M |
|
154.14M |
|
154.14M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$276.77M |
|
-- |
|
$14.73M |
|
$291.50M |
|
$67.63M |
|
$111.04M |
|
$440.25M |
|
$507.87M |
|
$-216.38M |
|
$-216.38M |
|
$-216.38M |
|
127.17M |
|
| Cash Flow Statement Financials | |
$-29.71M |
|
$-0.03M |
|
$-0.58M |
|
$261.34M |
|
$231.01M |
|
$-30.33M |
|
$2.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.09 |
|
-- |
|
-- |
|
-1.05 |
|
-0.53 |
|
82.66% |
|
-121.07% |
|
-121.07% |
|
-- |
|
-158.11% |
|
-158.11% |
|
$-29.74M |
|
-- |
|
-- |
|
-- |
|
0.07 |
|
0.76 |
|
0.67 |
|
134.00 |
|
15.24% |
|
15.24% |
|
-11.31% |
|
31.30% |
|
$-1.70 |
|
$-0.19 |
|
$-0.19 |
|